CytRx Corporation (CYTR) Position Increased by Goldman Sachs Group Inc.
Goldman Sachs Group Inc. boosted its stake in CytRx Corporation (NASDAQ:CYTR) by 795.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 703,465 shares of the biotechnology company’s stock after acquiring an additional 624,863 shares during the period. Goldman Sachs Group Inc. owned 0.42% of CytRx Corporation worth $441,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in shares of CytRx Corporation during the first quarter worth $102,000. LMR Partners LLP acquired a new stake in shares of CytRx Corporation during the second quarter worth $235,000. Renaissance Technologies LLC acquired a new stake in shares of CytRx Corporation during the first quarter worth $264,000. Finally, Vanguard Group Inc. raised its holdings in shares of CytRx Corporation by 53.9% during the second quarter. Vanguard Group Inc. now owns 4,823,123 shares of the biotechnology company’s stock worth $3,024,000 after purchasing an additional 1,689,874 shares during the period. 47.10% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CytRx Corporation (NASDAQ CYTR) opened at $1.86 on Wednesday. CytRx Corporation has a twelve month low of $1.71 and a twelve month high of $6.00.
Separately, ValuEngine cut shares of CytRx Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.
CytRx Corporation Company Profile
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.
Receive News & Stock Ratings for CytRx Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx Corporation and related stocks with our FREE daily email newsletter.